PEGylation Extends Circulation Half-Life While Preserving In Vitro and In Vivo Activity of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Batra, Jyotica ^a   Robinson, Jessica ^a,b   Mehner, Christine ^a   Hockla, Alexandra ^a   Miller, Erin ^a   Radisky, Derek C ^a   Radisky, Evette S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE; LYSINE; PEGYLATED RECOMBINANT TISSUE INHIBITOR OF METALLOPROTEINASE 1; RECOMBINANT ENZYME; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GELATINASES; HALF-LIFE; HUMANS; LYSINE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; NEOPLASM INVASIVENESS; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

MUS;

EID: 84869789997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050028     Document Type: Article

References (76)

1. Stamenkovic I, (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448-464.
2. Murphy G, Nagase H, (2008) Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308.
3. Gill SE, Parks WC, (2008) Metalloproteinases and their inhibitors: regulators of wound healing. International Journal of Biochemistry and Cell Biology 40: 1334-1347.
4. Radisky ES, Radisky DC, (2010) Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 15: 201-212.
5. Brew K, Dinakarpandian D, Nagase H, (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283.
6. Murphy G, (2011) Tissue inhibitors of metalloproteinases. Genome Biology 12: 233.
7. Hu J, Van den Steen PE, Sang QX, Opdenakker G, (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6: 480-498.
8. Kessenbrock K, Plaks V, Werb Z, (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
9. Vandenbroucke RE, Dejonckheere E, Libert C, (2011) A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? European Respiratory Journal 38: 1200-1214.
10. Newby AC, (2012) Matrix metalloproteinase inhibition therapy for vascular diseases. Vascular Pharmacology 56: 232-244.
11. Coussens LM, Fingleton B, Matrisian LM, (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
12. Turk B, (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
13. Burrage PS, Brinckerhoff CE, (2007) Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 8: 293-303.
14. Fingleton B, (2008) MMPs as therapeutic targets-Still a viable option? Semin Cell Dev Biol 19: 61-68.
15. Brand K, (2002) Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Curr Gene Ther 2: 255-271.
16. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF, (1988) Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 48: 5539-5545.
17. Alvarez OA, Carmichael DF, DeClerck YA, (1990) Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589-595.
18. Yamauchi K, Ogata Y, Nagase H, Shirouzu K, (2001) Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 31: 791-798.
19. Ohtani Y, Aoe M, Hara F, Tao H, Koshimune R, et al. (2006) Suppression effects of human recombinant tissue inhibitor of metalloproteinases-1(TIMP-1) on tumor proliferation using in vivo treatment model of well-differentiated colon cancer cell line, HT29. Acta Med Okayama 60: 257-266.
20. Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, et al. (1999) Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 162: 4212-4219.
21. Kurschat P, Graeve L, Erren A, Gatsios P, Rose-John S, et al. (1995) Expression of a biologically active murine tissue inhibitor of metalloproteinases-1 (TIMP-1) in baculovirus-infected insect cells. Purification and tissue distribution in the rat. Eur J Biochem 234: 485-491.
22. Black RA, Durie FH, Otten-Evans C, Miller R, Slack JL, et al. (1996) Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem Biophys Res Commun 225: 400-405.
23. Harris JM, Chess RB, (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
24. Harris JM, Martin NE, Modi M, (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539-551.
25. Szymkowski DE, (2005) Creating the next generation of protein therapeutics through rational drug design. Curr Opin Drug Discov Devel 8: 590-600.
26. Veronese FM, Harris JM, (2008) Peptide and protein PEGylation III: advances in chemistry and clinical applications. Adv Drug Deliv Rev 60: 1-2.
27. Goodson RJ, Katre NV, (1990) Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (N Y) 8: 343-346.
28. Pepinsky RB, Shapiro RI, Wang S, Chakraborty A, Gill A, et al. (2002) Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J Pharm Sci 91: 371-387.
29. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, et al. (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology 37: 375-536.
30. Crombez L, Marques B, Lenormand JL, Mouz N, Polack B, et al. (2005) High level production of secreted proteins: example of the human tissue inhibitor of metalloproteinases 1. Biochem Biophys Res Commun 337: 908-915.
31. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, et al. (2012) Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem 287: 15935-15946.
32. Suzuki K, Kan CC, Hung W, Gehring MR, Brew K, et al. (1998) Expression of human pro-matrix metalloproteinase 3 that lacks the N-terminal 34 residues in Escherichia coli: autoactivation and interaction with tissue inhibitor of metalloproteinase 1 (TIMP-1). Biol Chem 379: 185-191.
33. Kurfürst MM, (1992) Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analytical Biochemistry 200: 244-248.
34. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, et al. (2005) Protein Identification and Analysis Tools on the ExPASy Server. In: Walker JM, editor. The Proteomics Protocols Handbook. Totowa, N.J.: Humana Press. 571-607.
35. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T, (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7: R444-454.
36. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, et al. (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 101: 4966-4971.
37. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES, (2011) The P(2)′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J 440: 95-105.
38. Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM, (2003) In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. Journal of Histochemistry and Cytochemistry 51: 821-829.
39. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, et al. (2005) Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118: 2143-2153.
40. Snoek-van Beurden PA, Von den Hoff JW, (2005) Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38: 73-83.
41. Abatan OI, Welch KB, Nemzek JA, (2008) Evaluation of saphenous venipuncture and modified tail-clip blood collection in mice. J Am Assoc Lab Anim Sci 47: 8-15.
42. Bateman KP, Castonguay G, Xu L, Rowland S, Nicoll-Griffith DA, et al. (2001) Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 754: 245-251.
43. Durschlag M, Wurbel H, Stauffacher M, Von Holst D, (1996) Repeated blood collection in the laboratory mouse by tail incision-modification of an old technique. Physiol Behav 60: 1565-1568.
44. Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, et al. (1997) Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389: 77-81.
45. Roberts MJ, Bentley MD, Harris JM, (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54: 459-476.
46. Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, et al. (1999) Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem 274: 21362-21368.
47. Huang W, Meng Q, Suzuki K, Nagase H, Brew K, (1997) Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol Chem 272: 22086-22091.
48. Caterina NC, Windsor LJ, Yermovsky AE, Bodden MK, Taylor KB, et al. (1997) Replacement of conserved cysteines in human tissue inhibitor of metalloproteinases-1. J Biol Chem 272: 32141-32149.
49. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, et al. (1991) The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30: 8097-8102.
50. O'Connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G, (1994) Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem. 269: 14967-14973.
51. Ramachandran P, Boontheung P, Xie Y, Sondej M, Wong DT, et al. (2006) Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. Journal of Proteome Research 5: 1493-1503.
52. Radisky ES, Radisky DC, (2007) Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 8: 279-287.
53. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS, (2007) RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 121: 2307-2316.
54. Safina A, Ren MQ, Vandette E, Bakin AV, (2008) TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 27: 1198-1207.
55. Safina A, Vandette E, Bakin AV, (2007) ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 26: 2407-2422.
56. Himelstein BP, Canete-Soler R, Bernhard EJ, Muschel RJ, (1994) Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 107 (Pt 2): 477-486.
57. Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y, (1995) Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. British Journal of Cancer 71: 1039-1045.
58. Himelstein BP, Muschel RJ, (1996) Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts. Clin Exp Metastasis 14: 197-208.
59. Saad S, Bendall LJ, James A, Gottlieb DJ, Bradstock KF, (2000) Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 63: 105-115.
60. Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, et al. (2002) MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 72: 69-77.
61. Leader B, Baca QJ, Golan DE, (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7: 21-39.
62. Sa Y, Hao J, Samineni D, Clark J, Pyne-Geithman G, et al. (2011) Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats. Neurological Research 33: 433-438.
63. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
64. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, et al. (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9: 34-46.
65. Olson MW, Gervasi DC, Mobashery S, Fridman R, (1997) Kinetic analysis of the binding of human matrix metalloproteinase-2 and-9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 272: 29975-29983.
66. Vempati P, Karagiannis ED, Popel AS, (2007) A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 282: 37585-37596.
67. Ogata Y, Itoh Y, Nagase H, (1995) Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 270: 18506-18511.
68. Kolkenbrock H, Orgel D, Hecker-Kia A, Zimmermann J, Ulbrich N, (1995) Generation and activity of the ternary gelatinase B/TIMP-1/LMW-stromelysin-1 complex. Biol Chem Hoppe Seyler 376: 495-500.
69. Ogata Y, Enghild JJ, Nagase H, (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267: 3581-3584.
70. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, et al. (1999) Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274: 13066-13076.
71. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL, (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583-4591.
72. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, et al. (2009) Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 284: 25854-25866.
73. Chaturvedi M, Figiel I, Sreedhar B, Kaczmarek L (2012) Neuroprotection from Tissue Inhibitor of Metalloproteinase-1 and its nanoparticles. Neurochemistry International.
74. Lee MS, Kim YH, Kim YJ, Kwon SH, Bang JK, et al. (2011) Pharmacokinetics and biodistribution of human serum albumin-TIMP-2 fusion protein using near-infrared optical imaging. Journal of Pharmacy & Pharmaceutical Sciences 14: 368-377.
75. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, et al. (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69: 1517-1526.
76. Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, et al. (2012) Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nature Medicine 18: 143-147.